The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Bayer; Bayer; Bayer; Bayer
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen
 
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Agenus; Agenus; Agenus; Agenus; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelis; Exelis; Exelis; Exelis; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Roche; Roche; Roche; Roche
Research Funding - Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
 
Anthony B. El-Khoueiry
No Relationships to Disclose
 
Richard D. Kim
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech; Genentech; Genentech; Genentech; Lilly; Lilly; Lilly; Lilly
Speakers' Bureau - Lilly; Lilly; Lilly; Lilly; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Novartis; Novartis; Novartis; Novartis
 
William P. Harris
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; NeoTherma Oncology; NeoTherma Oncology; NeoTherma Oncology; NeoTherma Oncology
Research Funding - Agios; Agios; Agios; Agios; ArQule; ArQule; ArQule; ArQule; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; BTG; BTG; BTG; BTG; Exelixis; Exelixis; Exelixis; Exelixis; Halozyme; Halozyme; Halozyme; Halozyme; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck
 
Max W. Sung
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
 
Dirk Waldschmidt
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; Baxalta/Shire; Baxalta/Shire; Baxalta/Shire; Bayer Health; Bayer Health; Bayer Health; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Falk Foundation; Falk Foundation; Falk Foundation; Ipsen; Ipsen; Ipsen; MSD; MSD; MSD; Novartis; Novartis; Novartis; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Servier; Servier; Servier; Sirtex Medical; Sirtex Medical; Sirtex Medical
Travel, Accommodations, Expenses - Bayer Health; Bayer Health; Bayer Health; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Sirtex Medical; Sirtex Medical; Sirtex Medical
 
Syma Iqbal
Honoraria - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Roche; Roche; Roche; Roche
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai
Research Funding - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai
 
Xiaojing (Amily) Zhang
Employment - Bayer; Bayer; Bayer; Bayer
 
Keiko Nakajima
Employment - Bayer; Bayer; Bayer; Bayer
Stock and Other Ownership Interests - Bayer; Bayer; Bayer; Bayer
Honoraria - Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I)
Travel, Accommodations, Expenses - Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I); Kyowa Hakko Kirin (I)
 
Peter R. Galle
No Relationships to Disclose